The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay.

While the clearance is only for use in certain groups, Novavax’s long-awaited OK is still seen by analysts as a “win” for the ...

Moderna said on Friday it has filed a marketing application for the review of its updated COVID-19 vaccine with the U.S. Food ...

According to the CDC, cases of myocarditis and pericarditis are rare with the vaccines and, in most cases, resolve within a ...

The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.'s COVID-19 vaccine, restricting its use to ...

The FDA granted Pfizer-BioNTech full approval for those 12 and older in ... the FDA and CDC are giving greater scrutiny to the shots. The FDA delayed the decision on the vaccine as it sought ...

U.S. Food and Drug Administration advisers unanimously recommended on Thursday that COVID-19 vaccines for the 2025-26 period ...

Pharmaceutical giant Pfizer Inc. PFE has signed a significant licensing agreement with China's 3SBio Inc. for an experimental ...

US health regulators have given final approval to Novavax's COVID vaccine after an unusual delay and have placed new ...

Novavax's COVID-19 vaccine, Nuvaxovid™, receives limited FDA approval and triggers $175M milestone payment. Commercial ...

The company said the submission for the vaccine, branded as Spikevax, is based on guidance from the FDA, which advised that the shots should be updated to target strains that are a part of JN.1 ...